Braveheart Bio Quarterly Balance Sheet
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Braveheart Bio financial position
As of Jun 30, 2026, Braveheart Bio reported total assets of $127.0 million against total liabilities of $9.3 million. Shareholders' equity was negative at -$95.9 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $122.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 13.63, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Braveheart Bio balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 122.83M | — | 2.00K | — |
| Total Current Assets | 123.44M | — | — | — |
| Property, Plant & Equipment | 23.00K | — | — | — |
| Total Assets | 126.96M | — | — | — |
| Accounts Payable | 2.67M | — | — | — |
| Total Current Liabilities | 9.06M | — | — | — |
| Total Liabilities | 9.34M | — | — | — |
| Shareholders' Equity | -95.91M | -78.39M | -477.00K | -99.00K |
| Retained Earnings | -95.91M | — | — | — |
| Net Cash (Debt) | 122.83M | — | 2.00K | — |
| Shares Outstanding | 7.54M | — | — | — |
This table shows 4 quarterly periods of Braveheart Bio's balance sheet, from Q2 2026 back to Q? 2025, across 11 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow BRVE's reporting calendar. What is a balance sheet?